Senetek obtained exclusive rights to RNAi anticancer technology for brain tumors and three compounds for the treatment of skin aging from the Institute of Bioorganic Chemistry of the Polish Academy of Sciences.
The anticancer technology uses RNAi to inhibit the production of tenascin-C, which when expressed seems to correlate with the level of brain tumor malignancy, explains Senetek. The technology was recently applied to patients with glioblastoma multiforme with resounding success, reports the company.
It was developed by the Institute in cooperation with Department of Neurosurgery and Neurotraumatology University of Medical Sciences in Poznan, Poland. "The current options for patients with brain tumors consist of treatments such as surgery and chemotherapy and/or radiotherapy; which have an average survival time of only eight to 10 months,” notes Frank Massino, CEO and chairman of Senetek. “This new technology works not only to prolong the survival of patients suffering from brain tumors, but possibly to cure them as well."
The collaboration will also provide Senetek compounds with differentiating benefits for treating skin aging and possibly other aging conditions through their use in licensed cosmeceutical, nutritional, and prescription products.
Under the terms of the collaborative agreement, Senetek will have rights for all applications of the in-licensed technologies in exchange for undisclosed royalty payments to be paid to the Institute upon commercialization.